TORCH and Special ID Assays
Siemens Healthineers provides TORCH and special infectious-disease assays for improved prenatal and specialty care.

TORCH and Special ID Assays
Contact Us

TORCH is an acronym for a group of infectious organisms, which in healthy individuals can lead to treatable and mild disease, but when acquired during pregnancy can cause significant birth defects and even fetal death. Therefore, recognizing maternal disease and monitoring the patient when diagnosed are important for clinicians treating patients. Understanding this group of illnesses can help clinicians counsel patients to prevent infection and address fetal outcomes if infected.

TORCH is comprised of the following:

Special Infectious Disease
Siemens Healthineers offers special infectious-disease (ID) assays* to help laboratories address critical and common infectious diseases and help clinicians make critical decisions. Siemens Healthineers offers the following special ID tests as part of a growing menu:

  • Epstein-Barr Virus (EBV) VCA IgG
  • Epstein-Barr Virus (EBV) VCA IgM
  • Epstein-Barr Virus (EBV) EBNA IgG
  • H. pylori IgG
  • Syphilis
  • Zika Virus

Siemens Healthineers offers TORCH and special ID testing assays for the ADVIA Centaur® Immunoassay Systems and IMMULITE® Immunoassay Systems.

Learn More about TORCH

Understanding this group of illnesses can help clinician’s counsel their patients to help prevent infection, and address fetal outcomes if infected.

Patient history and risk factors guide prenatal and maternal testing for TORCH. These tests are often performed in the first trimester of pregnancy.

Learn More about Toxoplasma

In healthy individuals, toxoplasma infection can be treated effectively if diagnosed early.

Toxoplasma gondii (T. gondii) is an intracellular parasitic protozoan that is a parasite of birds and mammals, with cats being the primary host. Infection is typically spread by eating raw or undercooked meat containing cysts or by coming in contact with oocyst-infected cat feces. Climate, dietary customs, and presence of cats influence the prevalence of T. gondii, which can vary considerably by geographical location and age.1

ADVIA Centaur Toxoplasma IgG and IgM Assay benefits

  • Detect toxoplasma IgG and IgM antibodies on a single automated system.
  • Consolidate TORCH and routine assay testing on one system to improve lab productivity.
  • Automate manual TORCH testing to reduce hands-on labor and increase efficiency.

Toxoplasma IgG and IgM assays are also available on IMMULITE systems.

Learn More about “Other” Infections

Other infections can include illnesses such as HIV.

The “O” in the acronym TORCH is for “Other,” which includes infectious diseases that are vertically transmitted and can cause damage to the developing fetus.

Learn More about Rubella

Rubella infection during pregnancy can be dangerous for a developing baby and can cause congenital rubella syndrome (CRS).

Rubella is a member of the togaviridae family. Primary infections are generally mild, with non-specific symptoms such as a mild rash, low-grade fever, and lymphadenopathy. In contrast, primary infections during pregnancy can pass transplacentally to the fetus and can lead to fetal death or congenital rubella syndrome (CRS). The risk of fetal infection is greatest during the first trimester of pregnancy. Babies born with CRS may exhibit low birth weight, deafness, eye disease, mental retardation, and cardiac abnormalities.1

ADVIA Centaur Rubella IgG and IgM Assay benefits

  • Detect rubella IgG and IgM antibodies with good sensitivity and specificity on an automated system.
  • Consolidate TORCH and routine assay testing on one system to improve lab productivity.
  • Automate manual TORCH testing to reduce hands-on labor and increase efficiency.

Rubella IgG and IgM assays are also available on IMMULITE systems.

Learn More about Cytomegalovirus (CMV)

Cytomegalovirus (CMV) is a member of the herpes-virus family and can be found in over half of adults by age 40.11 Most CMV infections are asymptomatic, but can cause serious health problems when passed congenitally, and with immunocompromised individuals (e.g. HIV-infected persons, organ transplant recipients).

The CMV IgG assay is now available on the Atellica® IM Analyzer and the ADVIA Centaur® XP/XPT and CP Immunoassay Systems.**

Benefits of the Siemens Healthineers CMV IgG Assay

  • Produce faster results and reduce costs by reducing repeat testing with no equivocal zone.
  • Achieve accuracy when determining CMV IgG patient serological status with a positive agreement of 99.6% and a negative agreement of 96.8%.
  • Reach a broader patient population at risk for CMV, with both adult and pediatric claims.


Learn More about Herpes Virus (HSV)

Type-specific diagnosis can guide duration and dosage of antiviral therapy.

Herpes simplex virus (HSV) causes acute and recurrent infections, which are often subclinical.2 However, it may cause generalized and fatal infection in newborns and immunocompromised people. Two types of HSV are serologically distinguishable: herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2).3

The ADVIA Centaur Herpes-1 IgG (HSV1) and Herpes-2 IgG (HSV2) type-specific assays are now available for the diagnosis of herpes infection.

ADVIA Centaur HSV1 and HSV2 Assay benefits

  • Detect HSV-1 or HSV-2 specific IgG antibodies with recombinant type-specific glycoproteins.
  • Consolidate TORCH and routine assay testing on one system to improve lab productivity.
  • Automate manual TORCH testing to reduce hands-on labor and increase efficiency.

The Herpes 1 and 2 IgG combined assay is available on IMMULITE systems.

Learn More about Epstein-Barr Virus (EBV)

EBV is the classic cause of infectious mononucleosis (IM) and is generally acquired by oral transmission of infected saliva.

Epstein-Barr virus (EBV) is a member of the herpes-virus family and a worldwide infectious agent that is the classic cause of infectious mononucleosis (IM).4 IM is often diagnosed based on the presentation of characteristic symptoms of sore throat, lymphadenopathy, and fever, along with a positive heterophile antibody test and a characteristic hematological picture of lymphocytosis (>50%) with 10% or more of the lymphocytes identified as atypical.5

EBV is generally acquired by oral transmission of infected saliva. Following multiplication in epithelial cells of the oropharynx, the virus selectively infects B lymphocytes in the peripheral blood and other reticuloendothelial tissues. EBV has been intimately associated with several human tumors, including African Burkitt lymphoma, nasopharyngeal carcinoma, Hodgkin's disease, and B-cell lymphomas and leiomyosarcomas in organ transplant recipients and patients with immunodeficiency disorders.6

Siemens Healthineers offers the following EBV panel on the IMMULITE® 2000 and IMMULITE® 2000 XPi systems.*

  • Epstein-Barr Virus (EBV) VCA IgG Assay
  • Epstein-Barr Virus (EBV) VCA IgM Assay
  • Epstein-Barr Virus (EBV) EBNA IgG Assay

Learn More about Helicobacter pylori (H. pylori)

Approximately two-thirds of the world’s population is infected with H. pylori, which can be treated with appropriate antibiotic regimens.

Helicobacter pylori (H. pylori) is a gram-negative bacteria that causes more than 90% of duodenal ulcers and up to 80% of gastric ulcers. Most individuals infected with H. pylori are asymptomatic. However, H. pylori is associated with gastritis and duodenal and gastric ulcers. Infected persons have an increased risk of developing gastric cancer and mucosa-associated lymphoid type (MALT) lymphoma compared to the noninfected. Appropriate antibiotic regimens can eradicate the infection in most patients, with complete resolution of inflammation and a minimal chance of ulcer recurrence.7

There are multiple laboratory methods to detect H. pylori infection, including the H. pylori fecal antigen test, carbon-13 urea breath test, antibiogram, and H. pylori serology.

Siemens Healthineers offers an H. pylori IgG assay on IMMULITE systems.

Learn More about Syphilis

Untreated syphilis cases may result in serious complications, and can cause life-threatening damage to a fetus if vertically transmitted during pregnancy.

Syphilis can be considered part of the TORCH panel (falling under the “Other” category). Syphilis is a sexually transmitted disease that can cause serious health problems if left untreated. Syphilis is divided into stages—primary, secondary, latent, and tertiary—with different signs, symptoms, and diagnostic features.8

The U.S. Preventive Services Task Force recommends that the following groups be tested for syphilis:

  • All pregnant women should be tested at their first prenatal visit. For high-risk women, many organizations recommend repeat serologic testing in the third trimester and at delivery.
  • Individuals who participate in high-risk activities, such as commercial sex workers, persons who exchange sex for drugs, those with other sexually transmitted diseases (including HIV), and contacts of persons with active syphilis, should be tested.

The ADVIA Centaur Syphilis Assay offers good assay performance

  • Receive results quickly with a treponemal antibody test that has good precision and good agreement with a comparative automated syphilis assay.
  • Detect true positives with good sensitivity and reduce false positives with good specificity.
  • Consolidate syphilis testing with other high-volume ID, TORCH, and routine assays on one system to improve lab productivity.

Syphilis (treponemal antibody) is also available on the IMMULITE® 2000 and IMMULITE® 2000 XPi systems.

Learn More about Zika Virus

Zika virus infection during pregnancy is associated with congenital Zika syndrome, which includes a pattern of birth defects in fetuses and babies.

Zika Virus
Zika virus (ZIKV) is a single-stranded, positive-sense RNA virus.9 ZIKV belongs to the Flaviviridae family, which includes dengue, West Nile, and yellow fever viruses.10 ZIKV was first isolated from rhesus monkeys in the Zika forest of Uganda in 1947.9 In humans, ZIKV infection was first reported in Nigeria in 1954. The first ZIKV epidemic was reported on the Western Pacific Island of Yap in 2007 and later epidemics in French Polynesia in 2013 and 2014. In the Americas, a ZIKV outbreak first emerged in Brazil in March 2015 and spread to several countries and territories by March 2016.10

ZIKV is mainly transmitted by bites from infected mosquitos. Transmission from mother to fetus during pregnancy, through sexual contact with infected partners,10 and potentially through blood transfusion has been documented.9

The ADVIA Centaur Zika Test
The automated ADVIA Centaur® Zika Test is now available to help address the growing public-health challenge presented by the emergence of the Zika virus.

ADVIA Centaur Zika Test Benefits

  • Detect positive infections with limited cross-reactivity to other flaviruses 8 days after onset of symptoms or risk of exposure.
  • Consolidate infectious-disease testing on one automated system—the ADVIA Centaur XP/XPT Immunoassay System.
  • Improve lab efficiency by using an automated test that can be used with serum and plasma samples and has good onboard stability and a long calibration interval.

Share this page:

Related Products, Services & Resources

*System and assay availability is subject to local regulatory requirements.
**The ADVIA Centaur and Atellica IM CMV IgG assays are not intended for blood and tissue donor screening.
Not available for sale in the U.S.
The ADVIA Centaur Zika Test has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories, only for the diagnosis for Zika virus infection and not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of Zika virus and/or diagnosis of Zika virus infection under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

1. Armstrong AS, Safford JW, Holbert DN, Mushahra IK. Congenital diseases of microbiological origin. In: Wood D, ed. The immunoassay handbook: applications. New York: Stockton Press; 1994:499-501.
2. Centers for Disease Control and Prevention. Genital Herpes—CDC Fact Sheet. Updated February 19, 2016. Accessed September 8, 2016.
3. Wald A, Ashley-Morrow R. Serological testing for herpes simplex virus (HSV)-1 and HSV-2 infection. Clin Infect Dis. 2002;35(suppl 2):S173-S182.
4. Jenson HB, Baltimore RS. Infectious mononucleosis. Pediatric infectious diseases: principles and practice. Norwalk, Conn. Appleton & Lange, 1995: 565-76.
5. Henle W, Henle G. Epstein-Barr virus and infectious mononucleosis. In: Human herpesvirus infections: clinical aspects. New York: Marcel Dekker, 1982.

6. Gaffey MJ, Weiss LM. Association of Epstein-Barr virus with human neoplasia. Pathol Ann. 1992;27:55-74.
7. CDC Fact Sheet.
9. Musso D, Gubler DJ. Zika virus. Clin Microbiol Rev. 2016 Jul;29(3):487-524.
10. Petersen LR, Jamieson DJ, Powers AM, Honein MA. N Engl J Med. 2016 Apr 21;374(16):1552-63.